Investment Rating - The report maintains a "Buy" rating for the company [2][7] Core Views - The company demonstrated revenue and profit growth in the first half of 2024, with revenue reaching 1.138 billion yuan, a year-on-year increase of 9.7%, and net profit attributable to shareholders of 115 million yuan, up 3.2% year-on-year [3][4] - The company's business model shows strong synergy, particularly in the beauty and health sectors, with significant growth in sub-segments such as sub-health management services, which grew by 50% year-on-year [4][5] - The company is expanding its market presence through both organic growth and acquisitions, enhancing operational efficiency through digital marketing tools [7] Revenue Performance - The company's revenue for 1H2024 was 1.138 billion yuan, with a year-on-year growth of 9.7% [3] - The adjusted net profit for the same period was 1.32 billion yuan, reflecting a 0.5% increase year-on-year [3] - Revenue breakdown by business segments shows beauty and health services at 620 million yuan, medical beauty services at 440 million yuan, and sub-health medical services at 70 million yuan, with respective year-on-year growth rates of 13.6%, 0.3%, and 50.0% [4] Operational Efficiency - The company reported an increase in gross margin to 47.0%, up 0.9 percentage points year-on-year, while the net profit margin slightly decreased to 10.1%, down 0.6 percentage points [4][5] - The gross margins for the beauty and health, medical beauty, and sub-health business segments were 40.3%, 55.1%, and 54.4%, respectively, with notable improvements in the sub-health segment [5] Market Data - The total market capitalization of the company is 3.754 billion HKD, with a total share count of 236 million shares [3] - The stock price has fluctuated between 9.11 and 17.50 HKD over the past year [3] Financial Forecast - The company is projected to achieve revenues of 2.596 billion yuan in 2024, with a growth rate of 21.03%, and net profit of 250 million yuan, reflecting a growth rate of 15.91% [8][9] - The earnings per share (EPS) are expected to be 1.06 yuan in 2024, with a price-to-earnings (P/E) ratio of 14 [8][12]
美丽田园医疗健康：2024年中报点评：上半年营收利润逆势双增，三美模式协同性彰显